

Ewa Gogola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5140318/publications.pdf>

Version: 2024-02-01

14
papers

3,537
citations

567281

15
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

6070
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. <i>Molecular Cell</i> , 2021, 81, 4692-4708.e9.	9.7	40
2	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 235-254.	4.5	47
3	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. <i>Cell Reports</i> , 2018, 23, 100-111.	6.4	60
4	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. <i>Nature Methods</i> , 2018, 15, 134-140.	19.0	110
5	A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. <i>Cell</i> , 2018, 172, 373-386.e10.	28.9	1,201
6	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. <i>Cell Reports</i> , 2018, 23, 2107-2118.	6.4	110
7	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. <i>Cancer Cell</i> , 2018, 33, 1078-1093.e12.	16.8	238
8	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. <i>Nature Cell Biology</i> , 2017, 19, 1371-1378.	10.3	257
9	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. <i>Nature Communications</i> , 2017, 8, 15981.	12.8	83
10	TRIM28 Is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming. <i>Stem Cells</i> , 2017, 35, 147-157.	3.2	43
11	Replication fork stability confers chemoresistance in BRCA-deficient cells. <i>Nature</i> , 2016, 535, 382-387.	27.8	685
12	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8409-8414.	7.1	106
13	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. <i>Nature</i> , 2015, 521, 541-544.	27.8	487
14	Studying cancer drug resistance using BRCA-deficient mouse mammary tumor organoids. <i>Protocol Exchange</i> , 0, , .	0.3	1